
Browsing restrictions can be lifted for a fee.
BiOptic Inc., a biotechnology instrumentation company, develops scientific products for research and clinical applications. It offers instruments, such as bio-fragment analyzers and PCR thermocyclers; consumables, including DNA, RNA, and protein cartridges, as well as quantification kits; premix and polymerase PCR reagents; and veterinary, human, and food related testing kits. BiOptic Inc.was founded in 1993 and is headquartered in New Taipei City, Taiwan.
6850
光鼎生技
-3.49%
(-0.03)
The most recent financial report for 光鼎生技 (6850) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6850's short-term business performance and financial health. For the latest updates on 6850's earnings releases, visit this page regularly.
According to historical valuation range analysis, 光鼎生技 (6850)'s current price-to-earnings (P/E) ratio is 51.43, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 光鼎生技 (6850) reported an Operating Profit of 18.29M with an Operating Margin of 17.07% this period, representing a growth of 998.74% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 光鼎生技 (6850) announced revenue of 107.17M, with a Year-Over-Year growth rate of 38.29%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 光鼎生技 (6850) held Total Cash and Cash Equivalents of 124.65M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 光鼎生技 (6850) achieved the “three margins increasing” benchmark, with a gross margin of 63.36%%, operating margin of 17.07%%, and net margin of 3.54%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6850's profit trajectory and future growth potential.
According to the past four quarterly reports, 光鼎生技 (6850)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.17. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
光鼎生技 (6850)'s Free Cash Flow (FCF) for the period is 17.87M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 276.55% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.